GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arctic Bioscience AS ABS.OL · NOK

Health Care · Oslo Børs · 🇳🇴 Norway

Compare

2.55

+6.69%

Close of 9 Nov 2026, in NOK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in NOK, from our data supplier.

FY2025

Revenue

NOK 40.1m

FY2018FY2025

Net income

−NOK 41.0m

FY2018FY2025

Free cash flow

−NOK 45.4m

FY2018FY2025

Shareholders' equity

NOK 173.5m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueNOK 40.1mNOK 43.5mNOK 33.8mNOK 34.3mNOK 21.5mNOK 20.5mNOK 30.0mNOK 24.8m
Research and development—NOK 2.3mNOK 2.6m———NOK 111,088NOK 197,023
Operating income−NOK 33.4m−NOK 47.8m−NOK 48.6m−NOK 37.4mNOK 40.6m−NOK 21.7m−NOK 3.1m−NOK 1.1m
Net income−NOK 41.0m−NOK 47.9m−NOK 45.5m−NOK 34.0m−NOK 42.6m−NOK 22.6m−NOK 4.0m−NOK 1.7m
Diluted earnings per share-1.54-1.88-1.80-1.39-1.75-0.93-0.15-0.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsNOK 284.7mNOK 279.7mNOK 300.3mNOK 327.7mNOK 341.5mNOK 93.2mNOK 82.5mNOK 45.4m
Cash and short-term investments—NOK 2.2mNOK 79.6mNOK 144.2mNOK 227.4mNOK 12.6mNOK 23.4mNOK 368,783
Total liabilitiesNOK 111.2mNOK 69.0mNOK 41.7mNOK 40.4mNOK 20.9mNOK 29.3mNOK 18.6mNOK 23.5m
DebtNOK 27.4mNOK 32.9mNOK 2.0mNOK 1.1mNOK 4,185NOK 8.5mNOK 7.2mNOK 12.1m
Shareholders' equityNOK 173.5mNOK 210.7mNOK 258.6mNOK 287.3mNOK 320.6mNOK 63.9mNOK 63.9mNOK 21.9m
Shares outstanding27m25m25m24m24m24m27m27m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−NOK 22.7m−NOK 45.4m−NOK 40.3m−NOK 25.4m−NOK 39.5m−NOK 21.9mNOK 2.2m—
Capital spending−NOK 22.7m−NOK 50.8m−NOK 45.3m−NOK 58.6m−NOK 36.5m−NOK 13.4m−NOK 13.4m—
Free cash flow−NOK 45.4m−NOK 96.2m−NOK 85.6m−NOK 84.0m−NOK 76.0m−NOK 35.3m−NOK 11.3m—

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023
RevenueNOK 18.7mNOK 27.2mNOK 17.2mNOK 8.6mNOK 14.7mNOK 7.3mNOK 19.1mNOK 7.8m
Operating income−NOK 16.2m−NOK 23.6m−NOK 24.2m−NOK 12.1m−NOK 26.0m−NOK 13.0m−NOK 22.6mNOK 1.2m
Net income−NOK 18.9m−NOK 24.4m−NOK 23.5m−NOK 11.8m−NOK 24.9m−NOK 12.4m−NOK 20.7m—
Diluted earnings per share-0.71-0.96-0.92-0.46-0.98-0.49-0.82—
Cash from operations−NOK 21.0m−NOK 19.0m−NOK 25.0m−NOK 12.0m−NOK 12.0m−NOK 6.0m−NOK 27.0m—
Capital spending—−NOK 50.0m——−NOK 21.0m−NOK 10.0m−NOK 23.0m—
Free cash flow—−NOK 69.0m——−NOK 33.0m−NOK 16.0m−NOK 50.0m—
Total assetsNOK 290.3mNOK 279.7mNOK 273.2m—NOK 300.3m—NOK 321.5m—
Cash and short-term investmentsNOK 2.5mNOK 2.2mNOK 19.8m—NOK 78.5m—NOK 113.8mNOK 130.6m
DebtNOK 39.0mNOK 31.4mNOK 1.8m—NOK 5.6m—NOK 4.2m—
Shareholders' equityNOK 195.3mNOK 210.7mNOK 235.1m—NOK 258.6m—NOK 283.4m—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-5.2%9.3%—
Operating income-3.6%9.1%—
Net income6.4%12.7%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-97.2%-110.3%-76.6%—
Net margin-106.4%-111.1%-120.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-2.1-1.0-1.3-1.9-2.3
Price to sales2.91.11.81.85.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.